Form D · Other
Cello Therapeutics, Inc.
San Diego, CA · CIK 0001708130
Offering snapshot reported Aug 22, 2022 · SEC filing
- Reported sold
- $7.05M Offering amount: $20.1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 8, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 22, 2022 | Initial | $7,051,723 | No comparison | 3 | SEC filing |
| Jun 23, 2017 | Initial | $1,600,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456553
Source: Form D, filed Aug 22, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Wei Shen | Director |
| Lili Xie | Director |
| Jie Zhang | Director, Executive |
| Liangfang Zhang | Director |
| Huiqing Zhu | Director |
Issuer details
Industry: Other (See others in industry)
Address:
5945 Pacific Center Blvd., Suite 507
San Diego, CA, 92121
San Diego, CA, 92121